Table 2.
Summary of pre-clinical or ex vivo studies in infectious diseases reporting benefits of targeting inhibitory immune receptors
Infection | Cell type affected | Inhibitory Receptor | Target Species | Outcomes | Refs |
---|---|---|---|---|---|
HIV | CD4+; CD8+ T cells | PD-1; CTLA4 TIGIT; LAG3 | Humans/Mice |
|
37,38,43,64,159,160 |
SIV | CD8+ T cells | PD-1; PD-L1; CTLA4 | Macaques | PD-1 blockade expands functional virus-specific CD8 T cells and prolongs survival | 38,54,59 |
HBV | CD4+; CD8+ T cells | PD-1; CTLA4; 2B4; TIM3 | Humans (ex vivo)/mice/woodchuck |
|
84–86,89,97,98 |
HCV | CD4+; CD8+ T cells | PD-1; PD-L1 | Human |
|
161–164 |
Influenza | CD8+ T cells | PD-1, TIM3 | Mice |
|
165,166 |
TB | CD4+; CD8+ T cells | TIM3 | Mice | TIM3 blockade restores T cell function and improves bacterial control, particularly in chronically infected susceptible mice | 106 |
Listeria | CD8+ T cells | PD-L1 | Mice | PD-L1 plays an important costimulatory role for antigen-specific CD8 T cells | 167 |
Malaria | CD4+; CD8+T cells; B cells | PD-1; PD-L1; CTLA4; LAG3;TIM3 | Mice |
|
9,26,29,31 |
Toxoplasma | CD8+ T cells | PD-1 | Mice | Blockade of the PD-1-PD-L1 reinvigorates CD8+T-cell responses with prevention of mortality | 168 |
Leishmania | CD4+; CD8+ T cells | PD-1, PD-L1 | Mice | PD-1 blockade in vivo restored T cell proliferation and function with complete resolution of chronic lesions. | 169–171 |